Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome

Acta Neurologica Scandinavica

Volumn 128, Issue 2, 2013, Pages 91-99

  Cramer, J A ^a   Sapin, C ^b   Francois C ^b  

^a Lundbeck SAS ^*

^b Lundbeck   (France)

Author keywords

Clobazam; Cohen's d; Effect size; Felbamate; Lamotrigine; Lennox Gastaut syndrome; Rufinamide; Topiramate

Indexed keywords

CLOBAZAM; FELBAMATE; LAMOTRIGINE; PLACEBO; RUFINAMIDE; TOPIRAMATE;

ANTICONVULSANT THERAPY; ARTICLE; COMPARATIVE STUDY; DROP ATTACK; DRUG MEGADOSE; HUMAN; LENNOX GASTAUT SYNDROME; LOW DRUG DOSE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TONIC CLONIC SEIZURE;

CLOBAZAM; COHEN'S D; EFFECT SIZE; FELBAMATE; LAMOTRIGINE; LENNOX-GASTAUT SYNDROME; RUFINAMIDE; TOPIRAMATE;

ANTICONVULSANTS; BENZODIAZEPINES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; HUMANS; INTELLECTUAL DISABILITY; SPASMS, INFANTILE; TREATMENT OUTCOME; UNITED STATES;

EID: 84880172048     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12086     Document Type: Article

References (31)

1. Arzimanoglou A, French J, Blume WT et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009;8:82-93.
2. Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia 2011;52(Suppl 5):3-9.
3. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86.
4. Ioannidis JP, Haidich AB, Pappa M et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA 2001;286:821-30.
5. Hancock EC, Cross HH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2009:CD003277.
6. Verdian L, Yi Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut syndrome in the United Kingdom. Seizure 2010;19:1-11.
7. Benedict A, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. Pharmacoeconomics 2010;28:185-99.
8. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011;77:1473-81.
9. Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando, FL: Academic Press, 1985.
10. Cohen J. Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ: L. Erlbaum Associates, 1988.
11. The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328:29-33.
12. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med 1997;337:1807-12.
13. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52:1882-7.
14. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70:1950-8.
15. Lamotrigine summary of product characteristics. http://us.gsk.com/products/assets/us_lamictal.pdf (accessed 10 December 2012).
16. Topiramate summary of product characteristics. http://www.janssenmedicalinformation.com/assets/pdf/products/files/Topamax/pi/LIB-TOP-068362-08.pdf (accessed 10 December 2012).
17. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut Syndrome. Epilepsia 1989;30:422-9.
18. Inanaga K, Kumashiro H, Fukuyama Y, Ohtahara S, Shirouzu M. Clinical study of oral administration of DN-1417, a TRH analog, in patients with intractable epilepsy. Epilepsia 1989;30:438-45.
19. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998;39:495-501.
20. Ferrie CD, Patel A. Treatment of Lennox-Gastaut Syndrome (LGS). Eur J Paediatr Neurol 2009;13:493-504.
21. Saneto RP, Anderson GD. Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide. Ther Clin Risk Manag 2009;5:271-80.
22. Stafstrom CE. Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide. Neuropsychiatr Dis Treat 2009;5:547-51.
23. Wheless JW, Conry J, Krauss G, Mann A, LoPresti A, Narurkar M. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009;24:1520-5.
24. Wheless JW. Managing severe epilepsy syndromes of early childhood. J Child Neurol 2009;24:24S-32S; quiz 33S-6S.
25. Ferrie CD. Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome. Expert Rev Neurother 2010;10:851-60.
26. Wisniewski CS. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with Lennox-Gastaut syndrome. Ann Pharmacother 2010;44:658-67.
27. Glenny AM, Altman DG, Song F et al. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134, iii-iv.
28. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900.
29. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
30. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008;118:69-86.
31. Ng Y-T, Conry J, Paolicchi J et al. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav 2012;25:687-94.